Investigation of Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

What this Trial Is About

Researchers are studying adults with primary or secondary central nervous system malignancies, such as gliomas and brain metastases, to evaluate an investigational PET radiotracer called [C-11]-CS1P1. This tracer may help provide additional information about tumor activity, treatment response, and the tumor environment in these brain cancers. The study is a prospective, single-arm interventional imaging trial aiming to explore how tracer uptake patterns relate to MRI findings, treatments received, and clinical outcomes. Participants will receive a baseline [C-11]-CS1P1 PET scan using a PET/CT or PET/MR scanner after intravenous injection of the tracer. The scan acquisition will last up to 90 minutes. An optional brain MRI may also be performed. Participants will be invited for one follow-up PET scan within 24 months of the baseline scan, preferably within about 6 months after treatment, to assess changes in tracer uptake over time. Clinical care will not be affected by study participation. During the study, researchers will collect quantitative PET data such as standardized uptake values and tumor-to-background ratios, along with qualitative assessments of tracer patterns. These measures will be compared with MRI features, treatment history, and clinical outcomes including disease progression and survival. Participants will be monitored for any adverse events related to tracer administration and radiation exposure. The study aims to generate preliminary data to guide future research using [C-11]-CS1P1 PET imaging in central nervous system cancers.

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1